EOLSNasdaqPharmaceutical PreparationsUS GAAP · USD

Evolus, Inc.

Evolus, Inc. is a U.S.-based performance beauty company focused on cash-pay medical aesthetics. It commercializes Jeuveau®, a botulinum toxin for glabellar lines, and has begun launching Evolysse™, a line of injectable hyaluronic acid gels for wrinkles and folds.

Kysy yhtiöstä
Liikevaihto297milj. USD
+11,6 %v/v
Liikevoitto (EBIT)−32,7milj. USD
+5,1 %v/v
EBIT-marginaali−11,0%
+1,9 %-yks.v/v
Nettotulos−51,6milj. USD
−2,4 %v/v
Vapaa kassavirta−45,7milj. USD
−134,7 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−200−1000100200300milj. USD2020: 57 milj. USD2020: EBIT −153 milj. USD20202021: 100 milj. USD2021: EBIT −44 milj. USD20212022: 149 milj. USD2022: EBIT −65 milj. USD20222023: 202 milj. USD2023: EBIT −49 milj. USD20232024: 266 milj. USD2024: EBIT −34 milj. USD20242025: 297 milj. USD2025: EBIT −33 milj. USD2025297−33
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Evolus, Inc.

Liiketoiminta

Osuus liikevaihdosta
Injectable neurotoxins85 %

Jeuveau® is the company's commercial botulinum toxin product used by aesthetic practitioners for glabellar lines.

Injectable hyaluronic acid gels15 %

Evolysse™ is a collection of HA fillers for wrinkles, folds, and facial contour applications.

Commercial support programs0 %

Loyalty, pricing, and co-branded marketing programs that support practitioner adoption and repeat purchasing.

Tuotteet

Raportoitu · osuus liikevaihdosta
99,3%FY2025100 %
  • Products99,3 %
  • Services0,7 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Evolus sells primarily to licensed aesthetic practitioners who administer injectable treatments in the cash-pay beauty market. Demand is driven by clinics and providers seeking differentiated products, marketing support, and flexible pricing rather than reimbursement-based therapeutic products. The company also indirectly serves end consumers who pay out of pocket for aesthetic procedures.

Licensed aesthetic practitioners

Buy Jeuveau® and Evolysse™ to perform elective injectable treatments and retain patients in cash-pay aesthetics.

Medical spas and aesthetic clinics

Purchase products for recurring facial aesthetic procedures and respond to pricing, loyalty, and bundled offers.

Dermatology and plastic surgery practices

Use the products as part of broader aesthetic service menus and value clinical data and product differentiation.

International distribution partners

Help commercialize Jeuveau® and future Evolysse™ launches outside the U.S. where direct sales are not used.

Strategia

Evolus is building a cash-pay aesthetics franchise around Jeuveau® and the Evolysse™ filler line, using an aesthetic-only model to avoid reimbursement complexity and preserve pricing flexibility. Its strategy combines U.S. expansion, international launches, and digital customer engagement to grow practitioner adoption and broaden the product portfolio.

Grow Jeuveau® adoption in the U.S. and abroadLyhyt aikaväli

Jeuveau® is the core commercial product and funds the platform.

Scale Evolysse™ in the U.S. and EuropeKeskipitkä aikaväli

The HA filler line expands the addressable market and diversifies revenue.

Expand the product portfolio through approvals and partnershipsKeskipitkä aikaväli

A broader portfolio improves customer retention and competitive positioning.

Maantiede

2024

Evolus is headquartered in the United States and generates most revenue there, with Jeuveau® also sold in Canada, certain European countries, and Australia. The company launched Evolysse™ Form and Smooth in the U.S. in April 2025 and expects broader European launches in 2026, making international approvals and market access important to growth.

USA95 %
Other countries (US filing)4,9 %

Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.

Riskit

Evolus depends on continued adoption of elective aesthetic procedures, so consumer spending weakness, inflation, and tariffs can pressure demand and margins. The company also faces execution risk around regulatory approvals, international launches, and reliance on third-party manufacturers and partners for supply and commercialization.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Dependence on elective consumer spending1Tariffs and supply-chain cost inflation2Regulatory approval and launch timing3Manufacturing concentration4Competitive pricing pressure5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Dependence on elective consumer spendingVaikutus: KorkeaTodennäköisyys: Korkea

    Customers pay out of pocket, so demand is sensitive to confidence, inflation, and economic stress.

    Kohdistuu: Jeuveau® and Evolysse™ procedure volumes

  2. Tariffs and supply-chain cost inflationVaikutus: KorkeaTodennäköisyys: Korkea

    The company imports products and components through third-party manufacturers, making costs vulnerable to trade actions.

    Kohdistuu: Gross margin and inventory planning

  3. Regulatory approval and launch timingVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Future Evolysse™ products require FDA and other approvals before commercialization.

    Kohdistuu: Revenue timing and product pipeline

  4. Manufacturing concentrationVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Jeuveau® and Evolysse™ rely on Daewoong and Symatese for production and supply.

    Kohdistuu: Product availability and quality control

  5. Competitive pricing pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Large aesthetics competitors can use rebates, coupons, and bundling to defend share.

    Kohdistuu: Market share and average selling price

Kysy Clarifolta: Evolus, Inc.

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition and net revenue adjustments

Gross sales are reduced by rebates, loyalty rewards, and marketing programs, affecting reported revenue and comparability.

Vaikutus: Net revenue and gross margin

Service revenue in Canada

Canadian Jeuveau® sales through a partner are recorded on a net basis as service revenue rather than product revenue.

Vaikutus: Revenue mix and margin presentation

Contingent royalty obligation fair value

The liability is valued using projected revenues, discount rates, and timing assumptions, creating earnings volatility.

Vaikutus: Operating expenses and balance sheet liabilities

Inventory and launch-related build

Inventory purchases for Evolysse™ launches and tariff protection can affect cash flow and period-end inventory balances.

Vaikutus: Working capital and cash flow

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Evolent Health, Inc.

EVH · Services-Management Services

Evolution

EVO · Consumer Discretionary

AbbVie Inc.

ABBV · Pharmaceutical Preparations

Evolv Technologies Holdings, Inc.

EVLV · Computer Peripheral Equipment, NEC

Evofem Biosciences, Inc.

EVFM · Pharmaceutical Preparations

Evommune, Inc.

EVMN · Pharmaceutical Preparations

Päivitetty: 24.9.2026

Evolus, Inc. (EOLS) liikevaihto, tulos ja tunnusluvut 2025 – Clarifo